Price (delayed)
$4.65
Market cap
$100.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$11.16
Enterprise value
$78.09M
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the
There are no recent dividends present for AGEN.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.